Approved antiviral drugs over the past 50 years

E De Clercq, G Li - Clinical microbiology reviews, 2016 - journals.asm.org
Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs
categorized into 13 functional groups have been formally approved for the treatment of the …

HIV infection

SG Deeks, J Overbaugh, A Phillips… - Nature reviews Disease …, 2015 - nature.com
More than 75 million people worldwide have been infected with human immunodeficiency
virus (HIV), and there are now approximately 37 million individuals living with the infection …

Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV

NI Paton, J Musaazi, C Kityo, S Walimbwa… - … England Journal of …, 2021 - Mass Medical Soc
Abstract Background The World Health Organization recommends dolutegravir with two
nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human …

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society–USA panel

HF Günthard, MS Saag, CA Benson, C Del Rio, JJ Eron… - Jama, 2016 - jamanetwork.com
Importance New data and therapeutic options warrant updated recommendations for the use
of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in adults. Objective To …

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority …

JM Llibre, CC Hung, C Brinson, F Castelli, PM Girard… - The Lancet, 2018 - thelancet.com
Background Lifelong HIV antiretroviral therapy (ART) has prompted an interest in two-drug
regimens to minimise cumulative drug exposure and toxicities. The safety, tolerability, and …

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 …

PE Sax, A Pozniak, ML Montes, E Koenig, E DeJesus… - The Lancet, 2017 - thelancet.com
Background Integrase strand transfer inhibitors (INSTIs) coadministered with two nucleoside
or nucleotide reverse transcriptase inhibitors (NRTIs) are recommended as first-line …

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and …

P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz… - The Lancet, 2019 - thelancet.com
Background Effective two-drug regimens could decrease long-term drug exposure and
toxicity with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy …

Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor–based regimens

J Norwood, M Turner, C Bofill, P Rebeiro… - JAIDS Journal of …, 2017 - journals.lww.com
Background: With the introduction of integrase strand transfer inhibitor (INSTI)-based
antiretroviral therapy, persons living with HIV have a potent new treatment option. Recently …

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

C Hoffmann, T Welz, M Sabranski, M Kolb, E Wolf… - HIV …, 2017 - Wiley Online Library
Objectives Dolutegravir (DTG), a second‐generation integrase strand transfer inhibitor
(INSTI), is now among the most frequently used antiretroviral agents. However, recent …

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society–USA Panel

HF Günthard, JA Aberg, JJ Eron, JF Hoy, A Telenti… - Jama, 2014 - jamanetwork.com
Importance New data and antiretroviral regimens expand treatment choices in resource-rich
settings and warrant an update of recommendations to treat adults infected with human …